Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment of murine fusariosis with SCH 56592.

Literature DB >> 10049271

Treatment of murine fusariosis with SCH 56592.

M Lozano-Chiu¹, S Arikan, V L Paetznick, E J Anaissie, D Loebenberg, J H Rex.

Abstract

Doses of 10 to 100 mg of the azole antifungal agent SCH 5692/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1999 PMID： 10049271 PMCID： PMC89164

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

21 in total

1. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis.

Authors: A M Sugar; X P Liu
Journal: Antimicrob Agents Chemother Date: 1996-05 Impact factor: 5.191

2. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.

Authors: K L Oakley; G Morrissey; D W Denning
Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.191

3. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors: J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal: Antimicrob Agents Chemother Date: 1997-07 Impact factor: 5.191

4. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains.

Authors: I Pujol; J Guarro; J Gené; J Sala
Journal: J Antimicrob Chemother Date: 1997-02 Impact factor: 5.790

5. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Authors: M A Pfaller; S Messer; R N Jones
Journal: Antimicrob Agents Chemother Date: 1997-02 Impact factor: 5.191

6. In vitro sensitivity of medically significant Fusarium species to various antimycotics.

Authors: A S Sekhon; A A Padhye; A K Garg; H Ahmad; N Moledina
Journal: Chemotherapy Date: 1994 Jul-Aug Impact factor: 2.544

7. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors: A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal: Antimicrob Agents Chemother Date: 1995-02 Impact factor: 5.191

Review 8. Fusarium infections in immunocompromised patients: case reports and literature review.

Authors: M Rabodonirina; M A Piens; M F Monier; E Guého; D Fière; M Mojon
Journal: Eur J Clin Microbiol Infect Dis Date: 1994-02 Impact factor: 3.267

Review 9. Taxonomy, biology, and clinical aspects of Fusarium species.

Authors: P E Nelson; M C Dignani; E J Anaissie
Journal: Clin Microbiol Rev Date: 1994-10 Impact factor: 26.132

Review 10. Opportunistic fusarial infections in humans.

Authors: J Guarro; J Gené
Journal: Eur J Clin Microbiol Infect Dis Date: 1995-09 Impact factor: 3.267

14 in total

1. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results.

Authors: Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal: Antimicrob Agents Chemother Date: 2002-10 Impact factor: 5.191

Review 2. Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors: Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal: Clin Pharmacokinet Date: 2010-06 Impact factor: 6.447

3. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.

Authors: F Barchiesi; A M Schimizzi; L K Najvar; R Bocanegra; F Caselli; S Di Cesare; D Giannini; L F Di Francesco; A Giacometti; F Carle; G Scalise; J R Graybill
Journal: Antimicrob Agents Chemother Date: 2001-05 Impact factor: 5.191

4. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida.

Authors: A Cacciapuoti; D Loebenberg; E Corcoran; F Menzel; E L Moss; C Norris; M Michalski; K Raynor; J Halpern; C Mendrick; B Arnold; B Antonacci; R Parmegiani; T Yarosh-Tomaine; G H Miller; R S Hare
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191

5. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.

Authors: R Petraitiene; V Petraitis; A H Groll; T Sein; S Piscitelli; M Candelario; A Field-Ridley; N Avila; J Bacher; T J Walsh
Journal: Antimicrob Agents Chemother Date: 2001-03 Impact factor: 5.191

6. Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

Authors: M Simitsopoulou; C Gil-Lamaignere; N Avramidis; A Maloukou; S Lekkas; E Havlova; L Kourounaki; D Loebenberg; E Roilides
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191